Sulforaphane

c-Myc inhibitors (10,058-F4 and 10,074-G5) were obtained from Selleckchem (Houston, TX, USA). Artemisinin (ARTS), Dihydroartemisinin (DHA), Shikonin, Oridonin, Andrographolide, Baicalein, Sulforaphane and Luteolin (purity ≥98%) were purchased from Shanghai Yuanye Bio-Technology Co., Ltd. (Shanghai, China). RPMI-1640, Dulbecco’s Modified Eagle’s medium (DMEM), Opti-MEM and fetal bovine serum (FBS) were purchased from Gibco/BRL (Grand Island, NY, USA). Sulforhodamine B (SRB) and DMSO were purchased from Sigma-Aldrich (St. Louis, MO, USA). Homo c-Myc plasmid was obtained from Gene Pharma (Gene Pharma Co., Ltd., China). Primary antibodies against c-Myc and PD-L1 were purchased from Cell Signaling Technology (Beverly, MA, USA); β-actin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All secondary antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA).